

Amendments to the Claims

1. (Currently amended) A drug composition comprising a degradable gel with a saturated moisture content of from not less than 50 wt. % up to not exceeding 98 wt. % and a functional material, wherein the degradable gel decomposes and dissipates upon completion of release of the functional material, and where the functional material is a material which is useful in treatment of humans or other animals or in plant or pest control.
2. (Currently amended) A drug composition comprising a degradable gel with a saturated moisture content of from not less than 50 wt. % up to not exceeding 98 wt. % and a functional material, wherein the release rate of the functional material is controlled by controlling the saturated moisture content of the degradable gel, wherein the degradable gel decomposes and dissipates upon completion of release of the functional material, and where the functional material is a material which is useful in treatment of humans or other animals or in plant or pest control.
3. (Currently amended) The drug composition according to claim 1, wherein the functional material is at least one selected from the group of intrauterine administration drugs, intravaginal administration drugs, intratumoral administration drugs of endometriotic cyst, and intrapelvic administration drugs.
4. (Currently amended) The drug composition according to claim 2, wherein the functional material is at least one selected from the group of intrauterine administration drugs, intravaginal administration drugs, intratumoral administration drugs of endometriotic cyst, and intrapelvic administration drugs.
5. (Currently amended) The drug composition according to claim 1, wherein the functional material is danazol.
6. (Currently amended) The drug composition according to claim 2, wherein the functional material is danazol.

7. (Currently amended) The drug composition according to claim 1, wherein the degradable gel is a polysaccharide gel.
8. (Currently amended) The drug composition according to claim 2, wherein the degradable gel is a polysaccharide gel.
9. (Currently amended) The drug composition according to claim 7, wherein the polysaccharide gel is an anionic polysaccharide gel.
10. (Currently amended) The drug composition according to claim 8, wherein the polysaccharide gel is an anionic polysaccharide gel.
11. (Currently amended) The drug composition according to claim 1, wherein the degradable gel is a gel obtained through crosslinking reaction using a crosslinking agent.
12. (Currently amended) The drug composition according to claim 2, wherein the degradable gel is a gel obtained through crosslinking reaction using a crosslinking agent.
13. (Currently amended) The drug composition according to claim 11, wherein the crosslinking agent is an epoxy compound having not less than two epoxy groups per molecule.
14. (Currently amended) The drug composition according to claim 12, wherein the crosslinking agent is an epoxy compound having not less than two epoxy groups per molecule.
15. (Currently amended) The drug composition according to claim 13, wherein the epoxy compound is ethylene glycol diglycidyl ether.
16. (Currently amended) The drug composition according to claim 14, wherein the epoxy compound is ethylene glycol diglycidyl ether.

17. (Currently amended) The ~~drug composition~~ according to claim 1, wherein the ~~drug composition~~ further comprises a surfactant.
18. (Currently amended) The ~~drug composition~~ according to claim 2, wherein the ~~drug composition~~ further comprises a surfactant.
19. (Currently amended) The ~~drug composition~~ according to claim 17, wherein the surfactant is a nonionic surfactant.
20. (Currently amended) The ~~drug composition~~ according to claim 18, wherein the surfactant is a nonionic surfactant.
21. (Withdrawn) In a drug comprising a degradable gel and a functional material, a method for controlled release of a functional material characterized in that the rate of release is controlled by varying the saturated moisture content of the degradable gel.
22. (Withdrawn) A preparation process for a drug comprising the steps of:
(First step) mixing a functional material and surfactant so as to obtain a surfactant suspension comprising the functional material;
(Second step) dissolving the components of a degradable gel in such proportion to yield a 20 to 80 wt. % aqueous solvent so as to prepare the raw materials solution of a degradable gel;
and
(Third step) mixing the surfactant suspension comprising the functional material and the raw materials solution of a degradable gel, and adding a crosslinking agent so as to crosslink the raw materials of a degradable gel.
23. (New) The composition according to claim 1, wherein the saturated moisture content is from not less than 60 wt. % up to not exceeding 98 wt. %.
24. (New) The composition according to claim 2, wherein the saturated moisture content is from not less than 60 wt. % up to not exceeding 98 wt. %.

25. (New) The composition according to claim 1, wherein the saturated moisture content is from not less than 70 wt. % up to not exceeding 98 wt. %.
26. (New) The composition according to claim 2, wherein the saturated moisture content is from not less than 70 wt. % up to not exceeding 98 wt. %.
27. (New) The composition according to claim 1, wherein the saturated moisture content is from not less than 80 wt. % up to not exceeding 98 wt. %.
28. (New) The composition according to claim 2, wherein the saturated moisture content is from not less than 80 wt. % up to not exceeding 98 wt. %.
29. (New) The composition according to claim 1, wherein the degradable gel is a gel of at least one member selected from the group consisting of anionic polysaccharides, cationic polysaccharides, dextrans, chitosans, ribonucleic acids and deoxyribonucleic acids.
30. (New) The composition according to claim 2, wherein the degradable gel is a gel of at least one member selected from the group consisting of anionic polysaccharides, cationic polysaccharides, dextrans, chitosans, ribonucleic acids and deoxyribonucleic acids.